Rubius Therapeutics, Inc. (CIK: 0001709401) EDGAR, Information, Filings... CompaniesBIO.Com

Rubius Therapeutics, Inc.

Mailing address
399 BINNEY STREET, SUITE 300, CAMBRIDGE, Delaware, 02139
Phone
617-679-9600
State location
Massachusetts
State of incorporation
Delaware
Fiscal year end
December 31
SIC
2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
Filings
N/A

Rubius Therapeutics, Inc. (CIK: 0001709401) is an American company incorporated in the state of Massachusetts. Head office is located at 399 BINNEY STREET, SUITE 300, CAMBRIDGE, Massachusetts, 02139. Work in the industry 2836 - (CF Office: Office of Life Sciences) BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES). Rubius Therapeutics, Inc. is a public company and trade via Over-The-Counter (OTC).

Owner	Filings	Transaction Date	Type of Owner
Appelhans Dannielle	0001874962	Jan-31-2023	officer: CEO and President
Schaffert Susanne	0001938363	Jul-12-2022	director
AFEYAN NOUBAR	0001222012	Mar-19-2021	director, 10 percent owner
Flagship Ventures Fund IV, L.P.	0001503559	Mar-19-2021	10 percent owner
Flagship Ventures Fund IV General Partner LLC	0001508051	Mar-19-2021	10 percent owner
Flagship Ventures Fund V, L.P.	0001627639	Mar-19-2021	10 percent owner
Flagship Ventures Opportunities Fund I, L.P.	0001677345	Mar-19-2021	10 percent owner
Flagship Ventures Fund V General Partner LLC	0001724575	Mar-19-2021	10 percent owner
Flagship Ventures Opportunities Fund I General Partner LLC	0001725004	Mar-19-2021	10 percent owner
Carmona Jose	0001693612	Oct-01-2020	officer: Chief Financial Officer
Turka Laurence A.	0001800952	Jan-21-2020	officer: Chief Scientific Officer
Coughlin Christina M.	0001799032	Jan-06-2020	officer: Chief Medical Officer
Prener Anne	0001797917	Dec-17-2019	director
Keson-Brookes Maiken	0001693805	Nov-18-2019	officer: CLO & Corp. Secretary
Holles Natalie C.	0001580111	Mar-19-2019	director
CAGNONI PABLO J	0001205703	Jul-17-2018	director, officer: Chief Executive Officer
LANGER ROBERT	0001239757	Jul-17-2018	director
KANIA EDWIN M JR	0001255927	Jul-17-2018	10 percent owner
Epstein David R	0001445826	Jul-17-2018	director
Rosenblatt Michael	0001478797	Jul-17-2018	director
Cuss Francis M	0001490216	Jul-17-2018	director
Sohn Catherine A.	0001555132	Jul-17-2018	director
Flagship Ventures Fund IV-Rx, L.P.	0001590973	Jul-17-2018	10 percent owner
Pomerantz Roger	0001614936	Jul-17-2018	director
Flagship VentureLabs IV, LLC	0001642578	Jul-17-2018	10 percent owner
Symonds Jonathan	0001693550	Jul-17-2018	director
Flagship V VentureLabs Rx Fund, L.P.	0001724939	Jul-17-2018	10 percent owner
OH ANDREW M.	0001746614	Jul-17-2018	officer: Chief Financial Officer
NISSEN TORBEN STRAIGHT	0001746647	Jul-17-2018	officer: President
CARPENTER CHRISTOPHER L.	0001746845	Jul-17-2018	officer: Chief Medical Officer

Includes all SEC registration details as well as a list of all documents (S-1, Prospectus, Current Reports, 8-K, 10K, Annual Reports) filed by Rubius Therapeutics, Inc.

Filings	Format	Description	Filed/Effective	File/Film Number
15-12G	Document	Notice of termination of registration of a class of securities under Section 12(g) Acc-no: 0001104659-23-043593 (34 Act) Size: 12 KB	Apr-10-2023	001-38586 23811332
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000315066-23-002230 (34 Act) Size: 8 KB	Apr-10-2023	005-90775 23809901
8-K	Document	Current report filing Acc-no: 0001104659-23-042792 (34 Act) Size: 193 KB	Apr-06-2023	001-38586 23807061
25	Document	Notification filed by issuer to voluntarily withdraw a class of securities from listing and registration on a national securities exchange Acc-no: 0001104659-23-037737 (34 Act) Size: 11 KB	Mar-28-2023	001-38586 23769912
DEF 14A	Document	Definitive proxy statements Acc-no: 0001104659-23-030329 (34 Act) Size: 2116 KB	Mar-09-2023	001-38586 23718196
8-K	Document	Current report filing Acc-no: 0001104659-23-028428 (34 Act) Size: 200 KB	Mar-03-2023	001-38586 23704110
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001088875-23-000072 (34 Act) Size: 10 KB	Mar-03-2023	005-90775 23702345
PRER14A	Document	Preliminary revised proxy soliciting materials Acc-no: 0001104659-23-027696 (34 Act) Size: 2488 KB	Mar-02-2023	001-38586 23696548
4	Document	Statement of changes in beneficial ownership of securities Acc-no: 0001104659-23-026139 ( Act) Size: 4 KB	Feb-27-2023
PRE 14A	Document	Preliminary proxy statement not related to a contested matter or merger/acquisition Acc-no: 0001104659-23-025672 (34 Act) Size: 496 KB	Feb-27-2023	001-38586 23670148
10-K	Document	Annual report pursuant to section 13 and 15(d) Acc-no: 0001709401-23-000005 (34 Act) Size: 7422 KB	Feb-27-2023	001-38586 23670059
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001104659-23-025607 (33 Act) Size: 28 KB	Feb-27-2023	333-226226 23669995
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001104659-23-025606 (33 Act) Size: 28 KB	Feb-27-2023	333-231478 23669994
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001104659-23-025605 (33 Act) Size: 28 KB	Feb-27-2023	333-237103 23669993
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001104659-23-025604 (33 Act) Size: 28 KB	Feb-27-2023	333-255942 23669992
S-8 POS	Document	Post-effective amendment to a S-8 registration statement Acc-no: 0001104659-23-025602 (33 Act) Size: 28 KB	Feb-27-2023	333-264814 23669990
RW	Document	Registration Withdrawal Request Acc-no: 0001104659-23-024021 (NE Act) Size: 7 KB	Feb-22-2023	333-265482 23650488
8-K	Document	Current report filing Acc-no: 0001104659-23-024013 (34 Act) Size: 233 KB	Feb-22-2023	001-38586 23650481
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0001193125-23-038310 (34 Act) Size: 156 KB	Feb-14-2023	005-90775 23626052
SC 13G/A	Document	Amendment to Schedule filed to report acquisition of beneficial ownership of 5% or more of a class of equity securities by passive investors and certain institutions Acc-no: 0000315066-23-002039 (34 Act) Size: 8 KB	Feb-09-2023	005-90775 23605013

Recent 20 filings. View all Rubius Therapeutics, Inc. filings

Overall rating 5.0

Aug 22, 2022

Jean Bishop

Very good communication and delivery made within the timeframe I was advised of

Aug 22, 2022

Pelisari

young lad who new his job ansered questions and new what was best for me.

Aug 22, 2022

Ryan Storey

Huge help thank you for your help .. y'all make it so much easier

Rubius Therapeutics, Inc. overview
Rubius Therapeutics, Inc. job
Rubius Therapeutics, Inc. stock
Rubius Therapeutics, Inc. ownership
Rubius Therapeutics, Inc. CEO
Rubius Therapeutics, Inc. documents

Disclaimer: The information on the Service is provided with the understanding that the Company is not herein engaged in rendering legal, accounting, tax, or other professional advice and services. As such, it should not be used as a substitute for consultation with professional accounting, tax, legal or other competent advisers.